Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Escitalopram Decreases Symptoms of Major Depressive Disorder in Adolescents: Presented at AACAP - (DGDispatch)
    Cetuximab Continues to Increase Survival in Patients With Head and Neck Cancer for Up to 5 Years - (DGNews)
    Indacaterol Produces Effective Bronchodilation in Patients With COPD During 1 Year of Treatment: Presented at CHEST 2009 - (DGDispatch)
    FDA Approves Romidepsin Injection for Previously Treated T-Cell Lymphoma - (DGNews)
    Long-Term Treatment With Tiotropium Is Effective for Men, Women With COPD: Presented at CHEST 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Insulin-Dependent Diabetes in Long-Term Care: Practical Considerations
    • Patient-Centered Approaches to the Evaluation and Management of Atrial Fibrillation
      Optimizing Antihypertensive Therapy and Health and Economic Outcomes in a Managed Care Environment

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Rapid and Persistent Selection of the K103N Mutation as a Majority Quasispecies in a HIV1-Patient Exposed to Efavirenz for Three Weeks: A Case Report and Review of the Literature
        Reversible Cerebellar Syndrome Caused by Metronidazole
        Complete Remission of Severe Idiopathic Cold Urticaria on Interleukin-1 Receptor Antagonist (Anakinra)
        Rapid Resolution of Nitrofurantoin-Induced Interstitial Lung Disease
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        AIDS: Pancreatic Enzyme Supplements Might Counter Nutrient Malabsorption

        A DGReview of :"Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients"
        Alimentary Pharmacology & Therapeutics

        12/28/2001
        By Mark Greener


        Pancreatic enzyme supplements might reduce faecal fat loss in human immunodeficiency virus (HIV)-positive patients experiencing nutrient malabsorption.

        Nutrient malabsorption undermines prognosis among people with AIDS. As pancreatic insufficiency seems to contribute to malabsorption, researchers from the University Hospital of Palermo and other Italian centres assessed the efficacy of oral pancreatic enzyme supplements in 24 HIV-positive patients with fat malabsorption.

        During the open label, pilot study, researchers used steatocrits to assess faecal fat loss at entry and after two weeks during which patients did not receive pancreatic enzymes. They repeated steatocrits after patients had taken pancreatic extracts 1000 units of lipase per gram of ingested fat for two weeks.

        All patients showed raised faecal fat loss at baseline and following the two weeks without supplementation. Faecal concentrations of elastase-1, chymotrypsin or both were abnormally low in six patients at entry. Five patients developed abdominal pain and were unable to tolerate the supplements.

        In the remainder of patients, faecal fat loss declined after two week?s supplementation compared to baseline. In eight of the 19 patients who completed the two weeks of supplementation, steatocrit values were within normal limits.

        Steatocrit values at entry correlated with the Centers for Disease Control (CDC) HIV classification. Moreover, the decrease in faecal fat loss following supplementation also correlated positively with CDC class.

        The authors conclude that pancreatic enzyme supplements seem to be highly effective for reducing faecal fat loss in HIV-positive patients experiencing nutrient malabsorption. However, the authors add, double-blind studies are needed to confirm the results of this study.

        Alimentary Pharmacology & Therapeutics 2001;15:1619-1625 "Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send